tiprankstipranks
Atossa Therapeutics (GB:0HJ7)
LSE:0HJ7
Holding GB:0HJ7?
Track your performance easily

Atossa Therapeutics (0HJ7) Share Price & Analysis

0 Followers

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

7.29%8.02%0.29%75.14%
0.29% Other Institutional Investors
75.14% Public Companies and
Individual Investors

0HJ7 FAQ

What was Atossa Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Atossa Therapeutics’s market cap?
Currently, no data Available
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is Mar 27, 2025 which is in 95 days.
    How were Atossa Therapeutics’s earnings last quarter?
    Atossa Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.06 earnings per share for the quarter, the consensus estimate of -$0.06 by $0.
      Is Atossa Therapeutics overvalued?
      According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does Atossa Therapeutics pay dividends?
        Atossa Therapeutics does not currently pay dividends.
        What is Atossa Therapeutics’s EPS estimate?
        Atossa Therapeutics’s EPS estimate is -$0.06.
          How many shares outstanding does Atossa Therapeutics have?
          Atossa Therapeutics has 125,801,254 shares outstanding.
            What happened to Atossa Therapeutics’s price movement after its last earnings report?
            Atossa Therapeutics reported an EPS of -$0.06 in its last earnings report, expectations of -$0.06. Following the earnings report the stock price went same N/A.
              Which hedge fund is a major shareholder of Atossa Therapeutics?
              Among the largest hedge funds holding Atossa Therapeutics’s share is Graham Capital Management, L.P.. It holds Atossa Therapeutics’s shares valued at N/A.
                ---

                Company Description

                Atossa Therapeutics

                Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
                ---

                0HJ7 Earnings Call

                Q2 2023
                0:00 / 0:00
                ---

                0HJ7 Stock 12 Month Forecast

                Average Price Target

                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
                Similar Stocks
                Company
                Price & Change
                Follow
                Atossa Therapeutics
                Anixa Biosciences
                Geron
                ESSA Pharma
                Gritstone bio

                Best Analysts Covering 0HJ7

                1 Year
                Jason McCarthyMaxim Group
                1 Year Success Rate
                6/12 ratings generated profit
                50%
                1 Year Average Return
                +10.40%
                assigned a buy rating 12 days ago
                Copying Jason McCarthy's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +10.40% per trade.
                Popular Stocks
                ---
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis